Abstract
This letter refers to the recent demonstration that HIV-1 infected macrophages form specialized conduits that connect to B-cells (1). The conduit selectively transports the HIV-1 nef protein, providing nef with numerous means to interfere with cellular processes. Currently, no consideration of the connection between the conduit and the development of AIDS-related lymphoma (ARL) has been offered. ARL is one of the primary causes of death in the HIV-infected population and is related to B-cell proliferation and activation. In this letter we discuss several studies that link HIVinfected macrophages and specific forms of the nef protein to the development of ARL. The conduits discovered by Xu et al. [1] may lead to a better understanding of how HIV infection results in lymphomagenesis.
Keywords: HIV-1, AIDS-related lymphoma, macrophages, HIV-1 nef protein, Pathogenesis, B-cells, lymphomagenesis, virus-specific immunoglobin responses (IgG2 and IgA), CD40-dependent activation, metastatic, cytokines, cytidine deaminase-associated DNA, modification, Epstein Barr virus (EBV), tumorogenesis, immortalization, proliferation, tumor biopsies, Monocyte-derived, inflammation, malignancy, IFN, IL-4, IL-13, IL-10, viral load, MHC class II receptors, trans-golgi network (TGN), lysosomal degradation, myristoylation domain, cytosolic, dementia, mutation rate, RNAs
Current HIV Research
Title: HIV-1 Nef Protein Visits B-Cells via Macrophage Nanotubes: A Mechanism for AIDS-Related Lymphoma Pathogenesis?
Volume: 8 Issue: 8
Author(s): Susanna L. Lamers, Gary B. Fogel, Leanne C. Huysentruyt and Michael S. McGrath
Affiliation:
Keywords: HIV-1, AIDS-related lymphoma, macrophages, HIV-1 nef protein, Pathogenesis, B-cells, lymphomagenesis, virus-specific immunoglobin responses (IgG2 and IgA), CD40-dependent activation, metastatic, cytokines, cytidine deaminase-associated DNA, modification, Epstein Barr virus (EBV), tumorogenesis, immortalization, proliferation, tumor biopsies, Monocyte-derived, inflammation, malignancy, IFN, IL-4, IL-13, IL-10, viral load, MHC class II receptors, trans-golgi network (TGN), lysosomal degradation, myristoylation domain, cytosolic, dementia, mutation rate, RNAs
Abstract: This letter refers to the recent demonstration that HIV-1 infected macrophages form specialized conduits that connect to B-cells (1). The conduit selectively transports the HIV-1 nef protein, providing nef with numerous means to interfere with cellular processes. Currently, no consideration of the connection between the conduit and the development of AIDS-related lymphoma (ARL) has been offered. ARL is one of the primary causes of death in the HIV-infected population and is related to B-cell proliferation and activation. In this letter we discuss several studies that link HIVinfected macrophages and specific forms of the nef protein to the development of ARL. The conduits discovered by Xu et al. [1] may lead to a better understanding of how HIV infection results in lymphomagenesis.
Export Options
About this article
Cite this article as:
L. Lamers Susanna, B. Fogel Gary, C. Huysentruyt Leanne and S. McGrath Michael, HIV-1 Nef Protein Visits B-Cells via Macrophage Nanotubes: A Mechanism for AIDS-Related Lymphoma Pathogenesis?, Current HIV Research 2010; 8 (8) . https://dx.doi.org/10.2174/157016210794088209
DOI https://dx.doi.org/10.2174/157016210794088209 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer
Current Stem Cell Research & Therapy Prodrugs and Endogenous Transporters: Are They Suitable Tools for Drug Targeting into the Central Nervous System?
Current Pharmaceutical Design Recent Developments in Targeted Therapies of the RAF-MEK and PI3KAKT Pathways in Cancer Treatment
Current Cancer Therapy Reviews Landmark Studies of Targeted Therapies for Advanced Non-Small Cell Lung Cancer: A Guide for Pulmonologists
Current Respiratory Medicine Reviews One-Compound-Multi-Target: Combination Prospect of Natural Compounds with Thrombolytic Therapy in Acute Ischemic Stroke
Current Neuropharmacology Targeting of Leukemia-Initiating Cells to Develop Curative Drug Therapies: Straightforward but Nontrivial Concept
Current Cancer Drug Targets Is There an Increased Risk of Lymphoma and Malignancies Under Anti- TNF Therapy in IBD?
Current Drug Targets The Medicinal Chemistry of Novel Iron Chelators for the Treatment of Cancer
Current Topics in Medicinal Chemistry Molecular Docking and Dynamics Simulation of Vibrio anguillarum Aspartate Semialdehyde Dehydrogenase with Natural Product Caulerpin
Letters in Drug Design & Discovery Rho GTPases: Promising Cellular Targets for Novel Anticancer Drugs
Current Cancer Drug Targets The Biological Effects of Diagnostic Cardiac Imaging
Current Pharmaceutical Design Small Molecules ATP-Competitive Inhibitors of FLT3: A Chemical Overview
Current Medicinal Chemistry Metformin for Prevention and Treatment of Colon Cancer: A Reappraisal of Experimental and Clinical Data
Current Drug Targets Plant Troponoids: Chemistry, Biological Activity, and Biosynthesis
Current Medicinal Chemistry The Delivery of Personalised, Precision Medicines <i>via</i> Synthetic Proteins
Drug Delivery Letters PLK1 Inhibition: Prospective Role for the Treatment of Pediatric Tumors
Current Drug Targets Mevalonate Kinase Deficiency: Disclosing the Role of Mevalonate Pathway Modulation in Inflammation
Current Pharmaceutical Design Anti-Gene Strategies to Down-Regulate Gene Expression in Mammalian Cells
Current Pharmaceutical Design Targeting Apoptosis Pathway with Natural Terpenoids: Implications for Treatment of Breast and Prostate Cancer
Current Drug Targets Targeting DNA G-Quadruplex Structures with Peptide Nucleic Acids
Current Pharmaceutical Design